
2024 Exploration Update for Strategic Minerals JV
Reykjavík, May 13, 2025 (GLOBE NEWSWIRE) — ('Amaroq' or the 'Company' or the 'Corporation')
2024 Exploration Update for Strategic Minerals JV
Amaroq Advances its Strategic Minerals Vision — Welcoming Dr. Steve Garwin
TORONTO, ONTARIO – May 13, 2025 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mining company with a substantial land package of gold and strategic mineral assets in Southern Greenland, is pleased to provide an update on the 2024 exploration results across the Company's strategic minerals portfolio JV, Gardaq AS.
Highlights
General
Stendalen
South Greenland Copper Belt
Target North
Johan Dahl Land
Josva
1
Amaroq Awarded Johan Dahl Land Licence and Positive Initial Exploration Results,
22 January 2025
.
References to the accompanying presentation can be accessed on the website by clicking the link below:
https://www.amaroqminerals.com/investors/presentations/
.
James Gilbertson, VP Exploration for Amaroq, commented:
'2024 was a defining year for Amaroq's strategic minerals exploration. While not every drill target yielded economic results, each programme delivered valuable geological insights that are sharpening our focus on the most promising opportunities. Key highlights include the discovery of new porphyry and epithermal systems, confirmation of a cobalt-rich nickel-copper target at Stendalen, and strong early results at Ukaleq — all reinforcing South Greenland's untapped potential.
'We're also pleased to welcome Dr. Steve Garwin as Technical Advisor. His global expertise in porphyry and epithermal systems is already influencing our exploration strategy.
'With new drill data, geophysics, and assay results in hand, Amaroq is well positioned to prioritise 2025 follow-up programmes — including potential further drilling at Stendalen and Ukaleq. These next steps will be key in demonstrating the value of the Gardaq JV and its contribution to Amaroq's strategic growth.'
Overview of 2024 Exploration Programme
2024 Drill Locations
Stendalen
* Logged, sampled and detectORE assays received
Projection WGS 84 UTM zone 23N
All Core drilled at NQ diameter
Target North
Projection WGS 84 UTM zone 23N
All Core drilled at NQ diameter
Josva
Projection WGS 84 UTM zone 23N
All Core drilled at NQ diameter
Initial Review of Exploration Results
Stendalen
In 2024, while assays are still largely pending and expected later this quarter, drilling did confirm extensive Cu/Ni/Co sulphides concentrated throughout the system as well as along the basal contact of the gabbroic intrusion, supported by strong conductive signals identified through downhole electromagnetic surveys (DHEM).
Updated geological models from these drilling results incorporate fold structures (anticlines, synclines, and sheathing) that could act as key controls on mineralisation, particularly near the hypothesised feeder zone to the northwest. U-Pb zircon dating yielded an age of ~1804 Ma, predating the Ketilidian orogeny and aligning well with these observed structural features and deformation phases.
These results provide a number of promising drill targets and represent a significant step toward advancing Stendalen.
Further afield from Stendalen, Amaroq is looking to leverage off the geological and sulphide hosting experienced gained in the assessment for further identify potential ultramafic and volcanic-hosted mineralisation.
Copper Belt
In 2024, drilling at Josva tested the depth and strike extensions of the historic copper-bearing Josva Shear Zone. While low-grade copper mineralisation (primarily bornite and chalcopyrite) was intercepted, results were below economic thresholds, though they expanded understanding of the mineralised system and its structural controls. Work will now more towards an assessment of the strike and depth potential away from Josva.
*True lengths have not been determined but are estimated to be 70-100% of interval length
At Target North, scout drilling intersected low- to intermediate-sulphidation epithermal veins, with evidence of hydrothermal boiling textures. Although no economic mineralisation was encountered, the confirmation of a well-developed epithermal system provides compelling evidence of the region's broader potential to host Cu-Au epithermal targets. As such, exploration focus is now shifting to other regional targets along the belt where similar geological signatures may be present.
Further exploration across the Copper Belt identified the Ukaleq target that included gold grades up to 12.3 g/t Au and copper grades reaching 5.1%, indicative of a robust mineralizing system; as previously reported.
On top of this exploration efforts have identified at least a further four prospective porphyry/epithermal targets to be followed up during 2025.
New Licences
The Company has drawn on its geological expertise to apply for three additional mineral licences, targeting highly prospective opportunities across Greenland. These include the tier-one phosphate and critical minerals potential at Gardiner (East Greenland), the emerging REE and Nb-Ta target at Illerfissalik, and a potential Kiruna-style IOCG system at Minturn in northern Greenland.
Sampling and QAQC Disclosure
Surface Drilling
Drill core was cut in half using a diamond blade core saw. Cut lines were consistently drawn along the core foliation axis and the right-hand side of the core was sampled. All drill core samples were placed into thick polymer bags with a sample ticket. All samples were prepared at ALS Geochemistry's containerised preparation laboratory on-site at Nalunaq, before being packaged and sent to an accredited laboratory, ALS Geochemistry, Loughrea, Ireland, for analysis.
At Stendalen - Sample preparation scheme PREP-31BY was used on all samples. This involves crushing to 70% under 2 mm, rotary split off 1 kg, and pulverizing the split to better than 85% passing 75 microns. Samples were then analysed by 50 g fire assay and ICP-MS finish using method PGM-MS24 which has a low detection limit for Pt, Pd and Au. A second multielement assay analysis is run for 50 g using method ME-MS61r, where the sample is digested in 4-acid (perchloric, nitric, hydrofluoric and hydrochloric acids) and analysed by ICP-AES for all elements and ICP-MS for high concentration elements.
At Target North and Josva - Sample preparation scheme PREP-31BY was used on all samples. This involves crushing to 70% under 2 mm, rotary split off 1 kg, and pulverizing the split to better than 85% passing 75 microns. Samples were then analysed by 50 g fire assay and ICP-AES finish using method Au-ICP2, with overlimit method Au-GRA22 which has a gravimetric finish. A second multielement assay analysis is run for 50 g using method ME-MS61r, where the sample is digested in 4-acid (perchloric, nitric, hydrofluoric and hydrochloric acids) and analysed by ICP-MS for all elements. Samples were analysed for Si, Ti and Zr using pXRF method pXRF-34.
Amaroq's QA/QC program consists of the systematic insertion of certified reference materials of known base metal contents, blanks, and quarter core field duplicates at a rate of 1 in 20 (5%) per QA/QC type. In addition, ALS insert blanks and standards into the analytical process.
Grab Sampling
Grab samples were collected from outcrops through the use of geological picks and hammers. Where possible chip channel samples were collected across the width of the visible vein. Grab samples were packaged into thick polymer bags with a sample ticket and reviewed by the Company geological staff prior to submission.
All grab samples were prepared at ALS Geochemistry's containerised preparation laboratory on-site at Nalunaq, before being packaged and sent to an accredited laboratory, ALS Geochemistry, Loughrea, Ireland, for analysis. As with drill the surface drill core, samples underwent preparation scheme PREP-31BY. This involves crushing to 70% under 2 mm, rotary split off 1 kg, and pulverizing the split to better than 85% passing 75 microns. Samples were then analysed by 50 g fire assay with method Au-AA26 which has a detection limit of 0.01 ppm Au. Samples containing visible gold and samples considered to be the Main Vein were assayed with screen-metallics fire assay technique Au-SCR24 which has a detection limit of 0.05 ppm Au. This involves screening 1 kg of pulverised sample to 106 microns followed by a gravimetric assay of the entire plus fraction and a duplicate 50 g AAS assay of the minus fraction.
Grab sample QAQC procedures consisted of the systematic insertion of certified reference materials of known gold content, blanks, and field duplicates at a rate of 1 in 20 or 5% per QA/QC type. In addition, ALS insert blanks and standards into the analytical process.
Enquiries:
Amaroq Minerals Ltd.
Eldur Olafsson, Executive Director and CEO
eo@amaroqminerals.com
Ed Westropp, Head of Business Development and Corporate Affairs
ewe@amaroqminerals.com
Eddie Wyvill, Corporate Development
+44 (0)7713 126727
ew@amaroqminerals.com
Panmure Liberum Limited (Nominated Adviser and Corporate Broker)
Scott Mathieson
Nikhil Varghese
+44 (0) 20 7886 2500
Canaccord Genuity Limited (Corporate Broker)
James Asensio
Harry Rees
Tel: +44 (0) 20 7523 8000
Camarco (Financial PR)
Billy Clegg
Elfie Kent
Fergus Young
+44 (0) 20 3757 4980
For Corporation updates:
Follow @Amaroq_Minerals on X (Formerly known as Twitter)
Follow Amaroq Minerals Ltd. on LinkedIn
Further Information:
About Amaroq Minerals
Amaroq's principal business objectives are the identification, acquisition, exploration, and development of gold and strategic metal properties in South Greenland. The Company's principal asset is a 100% interest in the Nalunaq Gold mine. The Company has a portfolio of gold and strategic metal assets in Southern Greenland covering the two known gold belts in the region as well as advanced exploration projects at Stendalen and the Sava Copper Belt exploring for Strategic metals such as Copper, Nickel, Rare Earths and other minerals. Amaroq Minerals is continued under the Business Corporations Act (Ontario) and wholly owns Nalunaq A/S, incorporated under the Greenland Companies Act.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This press release contains forward-looking information within the meaning of applicable securities legislation, which reflects the Corporation's current expectations regarding future events and the future growth of the Corporation's business. In this press release there is forward-looking information based on a number of assumptions and subject to a number of risks and uncertainties, many of which are beyond the Corporation's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include but are not limited to the factors discussed under 'Risk Factors' in the Final Prospectus available under the Corporation's profile on SEDAR at
www.sedar.com
. Any forward-looking information included in this press release is based only on information currently available to the Corporation and speaks only as of the date on which it is made. Except as required by applicable securities laws, the Corporation assumes no obligation to update or revise any forward-looking information to reflect new circumstances or events. No securities regulatory authority has either approved or disapproved of the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Inside Information
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No. 596/2014 on Market Abuse ('UK MAR'), as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, and Regulation (EU) No. 596/2014 on Market Abuse ('EU MAR').
Qualified Person Statement
The technical information presented in this press release has been approved by James Gilbertson CGeol, VP Exploration for Amaroq Minerals and a Chartered Geologist with the Geological Society of London, and as such a Qualified Person as defined by NI 43-101.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ('Alvotech'), and Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy's and Alvotech's proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally. 'We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide,' said Róbert Wessman, chairman and CEO of Alvotech. 'We are happy to collaborate with Alvotech for the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide. Additionally, oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy's. Use of trademarksKeytruda® is a registered trademark of Merck Sharp & Dohme Corp. Sources[1] Accessed on June 4, 2025. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. For more information visit Alvotech's investor portal, and website or follow Alvotech on social media on LinkedIn, Facebook, Instagram, and YouTube. Alvotech Forward Looking StatementsCertain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech's expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'aim' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to develop or co-develop future products, including the proposed biosimilar to Keytruda®; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech's estimates of expenses and profitability; (6) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. About Dr. Reddy's Laboratories Ltd:Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. Over the last 25 years, our Biologics team has developed into a fully integrated organization with robust capabilities in the development, manufacture and commercialization of a range of biosimilar products in oncology and immunology. We have a current portfolio of six commercial products marketed in India, with some products marketed in more than 30 other countries. In addition, we have several products in the pipeline in oncology and auto-immune diseases in various stages of development for global launches across developed as well as emerging markets. We are also ramping up manufacturing capacity to support our global expansion plans. In 2024, we launched our first biosimilar in the United Kingdom, Versavo® (biosimilar bevacizumab). This follows our launch of pegfilgrastim in the U.S and Europe through our partner. Our biosimilars business has a key role to play in driving both near-term and long-term growth. For more information, log on to: Dr. Reddy's DisclaimerThis press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words 'may', 'will', 'should', 'expects', 'plans', 'intends', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', or 'continue' and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to, without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the 'Risk Factors' and 'Forward-Looking Statements' sections of our Annual Report on Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information contained herein. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product's label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products. ALVOTECH CONTACTSBenedikt StefanssonVP Investor Relations and Global DR. REDDY'S CONTACTS Priya K Richa Periwal Corporate Communications Head of Investor Relations priyak@ richaperiwal@ in to access your portfolio
Yahoo
an hour ago
- Yahoo
SandCo Sets New Quartz Sand Production Record with 15,000 Tons in 2024, Eyes Further Expansion into China Market and Critical Minerals
SandCo Sets New Quartz Sand Production Record with 15,000 Tons in 2024 LONDON and ASTANA, Kazakhstan, June 05, 2025 (GLOBE NEWSWIRE) -- SandCo, Central Asia's top-tier supplier of premium quartz sand, reported an unprecedented production total of 15,000 tons for 2024 due to an initial $10 million investment in extended production facilities. SandCo operates a fully integrated quartz sand production cycle, including mining, refining, and distribution. It outputs silica with over 98% purity, and the company is working to increase its purity through constant investment in R&D. Quartz sand is used in semiconductor fabrication, high-rise construction, and advanced filtration technologies for oil and gas applications. "Our record production in 2024 is just a first step in our rehaul. We are working to accelerate our international commercial and logistic capabilities," said CEO Sanzhar Zhumanalin. "Our goal for 2025 is to push production levels up to 25,000 tons and start expansion into China and the Middle East, where top-class quartz sand is becoming an edge in important industries linked to the digital economy," he stated. During 2024, SandCo supplied quartz sand for projects such as Tengizchevroil's hydraulic fracturing operations, the Kazakhstan Football Federation's development of 20 youth football fields, and municipal water filtration projects in different locations in Central Asia. Global market demand for premium quartz sand has risen in recent years, driven by robust growth in semiconductor manufacturing. The industrial quartz sand market is projected to grow at a yearly rate of 5.5% from 2026 to 2033, while the frac sand market, essential for extracting oil and gas, is expected to expand by USD 4.50 billion between 2024 and 2028, according to industry sources. Last year, the company developed a new rail spur to connect its Kariernoe quartz deposit to international trade routes, and specifically with China and Caspian Sea ports. The company considers that the One Belt One road initiative between China and Europe will make Kariernoe an important element in future international trade routes. Founded in 1999, SandCo is part of Kazakhstan's Namys Group. Over its 25-year operational history, SandCo has grown in infrastructure development and R&D investment. Current production facilities include Hitachi and Volvo technologies, with whom SandCo maintains long standing working relations. The company is committed to ensuring premium purity and exact particle dimensions ranging from 0.1 mm to 15 mm, which is in line with international industry standards. For the 2025-2030 period, SandCo plans to enhance its cleantech position, invest in integrating renewable energy, including solar power, and reduce its carbon footprint. Further planned investments include the adoption of automated packaging and digital quality-control systems. Additionally, SandCo is advancing recycling initiatives for spent proppants, specialized quartz sands utilized extensively in oil and gas extraction processes—to promote sustainability and support circular economy practices. The company's plans include becoming a major partner of critical materials production in the next 24 months. SandCo employs more than 200 specialists with long-term licenses. For more information: media@ DISCLAIMERThis press release contains statements regarding the future of the company and its innovations. Statements regarding the future may be accompanied by words such as "anticipate", "believe", "estimate", "wait", "pretend", "power", "plan", "potential", the use of future time and other terms of similar meaning. No undue reliance should be placed on these claims. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including uncertainty of the company's commercial success, ability to protect our intellectual property rights, and other risks. These statements are based on current beliefs and forecasts and refer only to the date of this press release. The company assumes no obligation to publicly update its forward-looking statements, regardless of whether new information, future events or any other circumstance arise. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or in any other jurisdiction where such offer or sale would be unlawful. A photo accompanying this announcement is available at in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Point and Funds Managed by Blue Owl Capital Close Oversubscribed $248 Million Home Equity Investment Rated Securitization
Point completes its fourth rated securitization, securing over $2 Billion in orders from investors, signaling further maturation of the home equity investment asset class Palo Alto, California, June 05, 2025 (GLOBE NEWSWIRE) -- Point, the leading home equity investment platform making homeownership more valuable and accessible, and funds managed by Blue Owl Capital ('Blue Owl') announced today that they have completed a rated securitization of Point's Home Equity Investment ('HEI') assets, issuing $248.6 million of rated asset-backed securities (the 'Transaction'). The Transaction is Point's fourth rated securitization and fifth overall. The Transaction closed on May 23, 2025. The issuer, Point Securitization Trust 2025-1, issued $162.2 million of senior class A-1 securities rated A (low) (sf), $35 million of mezzanine class A-2 securities rated BBB (low) (sf), $28.3 million of subordinate class B-1 securities rated BB (low) (sf), and $23.1 million of subordinate class B-2 securities rated B (high) (sf) (retained), all rated by Morningstar DBRS. A portion of the notes were acquired by accounts managed by an affiliate of Blue Owl. The Transaction drew significant interest from both new and repeat institutional investors, resulting in the Transaction being more than 8x oversubscribed. Co-sponsoring the Transaction with a subsidiary of Blue Owl, Point was the originator of all the HEIs in the securitization and will continue to service the assets. 'This past year has been transformative—for Point and for the entire HEI space,' said Eddie Lim, co-founder and CEO of Point. 'Investor demand has never been stronger, and the performance of our deals continues to outperform expectations. Our latest securitization was met with overwhelming enthusiasm, reinforcing that HEIs aren't just gaining traction—they're reshaping how homeowners access equity. We're just scratching the surface of what's possible.' Over the past 18 months, the rated securitization space for HEIs has entered a new phase of maturation. With multiple HEI-backed deals successfully rated, the asset class is seeing increased institutional recognition and investor confidence, with issuance volume doubling and the number of transactions tripling in 2024 alone[1]. According to Finsight[2], HEI-backed deals totaled $936 million across five transactions last year—up significantly from prior years. These transactions have helped set important benchmarks for credit quality, structure, and performance, signaling a shift from emerging to established within the alternative housing finance landscape. 'The Blue Owl Alternative Credit team and Point have a longstanding relationship dating back to 2018, and we are excited to continue our partnership with the Point team,' said Ivan Zinn, Head of Alternative Credit at Blue Owl. 'This marks the second Point transaction that Blue Owl has co-sponsored, and we look forward to doing many more together. The success of this transaction is a testament to the Point platform and validates the thesis that HEIs will continue to be a growing asset class.' Barclays Capital Inc. ('Barclays') was the sole-structuring agent for the issuance. Barclays, Citigroup Global Markets Inc., and Nomura Securities International Inc. were joint bookrunners on the Transaction, and East West Markets, LLC and Cantor Fitzgerald & Co. were co-managers on the Transaction. About Point Point is the leading home equity platform making homeownership more valuable and accessible. Point's flagship product, the Home Equity Investment (HEI), empowers homeowners to unlock their equity to eliminate debt, get through periods of financial hardship, and diversify their wealth – without adding to their monthly expenses. Point has worked with more than 15,000 homeowners, unlocking more than $1.5 billion in home equity. Point's HEI enables investors to access a previously untapped asset class – owner-occupied residential real estate. Founded in 2015 by Eddie Lim, Eoin Matthews, and Alex Rampell, Point is backed by top investors, including Westcap, Andreessen Horowitz, Ribbit Capital, Greylock Partners, Bloomberg Beta, Blue Owl Capital, Alpaca VC, and Prudential. The company is headquartered in Palo Alto, CA. For more information, please visit Blue Owl CapitalAbout Blue Owl: Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives®. With $273 billion in assets under management as of March 31, 2025, we invest across three multi-strategy platforms: Credit, GP Strategic Capital, and Real Assets. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation. Together with over 1,200 experienced professionals globally, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit [1] Source: [2] Source: CONTACT: Amanda Woolley Point 3603191738 awoolley@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data